Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Synthomer Plc | SYNT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.80 | 0.50% | 159.80 | 13:53:52 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 160.00 | 157.00 | 160.20 | 159.00 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 11/1/2024 13:36 by darrin1471 LOTM "They allowed the £1B purchase to go ahead without proper financing to be in place at the time. A criminal decision."At the time of the acquisition (28/10/2021) BofE rates were 0.1%, we were exiting covid and the SYNT share price was near all time highs. Congratulations to all of those who had a crystal ball in 2021 and shorted SYNT. The share price was not a sudden collapse but a long 2 year fall. There was plenty of opportunity to sell. Small investors either took their eye off the ball or stuck their heads in the sand. I don't have a crystal ball but today the SYNT mkt cap looks good value, higher than average risk with higher than average potential reward. I still hold no position long or short in SYNT. |
Posted at 09/10/2023 20:58 by tayle Paid a decent dividend and scheduled to pay a decent interim to. Then their markets seemed to disappear, not all their business is in nitrile gloves, no improvement this year but next year is milk and honey. The lady who got a 23% remuneration increase it's criminal after investors got fleeced. Need to change their name to Secret Service Industries. |
Posted at 28/3/2023 12:28 by justiceforthemany Investors Chronicle ViewThe last IC recommendation on Synthomer PLC shares was Buy at 109.00 on 28 Mar 2023 Read the full article |
Posted at 12/2/2023 20:55 by justiceforthemany SynthomerInvestors’ Chronicle Shares in this chemicals business have tumbled recently as demand for nitrile, a synthetic rubber used in surgical gloves, has ebbed along with the pandemic. Investors are especially concerned about elevated debt levels, but with the shares now on a 36% discount to book value the sell-off appears “overdone̶ Buy (155p) |
Posted at 12/10/2022 09:50 by aringadingding There is a real world side to this and a stock market side to this.Real world side, as per investor seminar taking place right now, they will sell some non-core assets, reduce leverage, cancel the dividend, and then EPS will be whatever it comes out as over the next few years (will be interesting to see). They are positioned in sectors with good sustainability tail winds and experiencing growth at slightly above GDP rates in market size. This to me sounds like a good real world business proposition. Interestingly they are saying the last 12 months revenue, to June 2022, of the assets they are retaining, would be £2.8bn. This is a very healthy number as compared to historical annual revenue. It is probably boosted by the weak pound if they have calculated the number at today's FX rate - which is fair enough really. In the stock market side, the market at the moment is unbelievably pessimistic about many stocks and this is just another/prime example. That to me adds up to an entirely classic buying opportunity. |
Posted at 30/9/2022 07:49 by meijiman Can't see the company doing a presentation to investors on Oct 12th without having a few positives. I bought yesterday in the mini panic. Yes there are some problems and debt is too high but the valuation looks too low. |
Posted at 29/9/2022 06:37 by boonkoh Now at a higher risk of breaching banking covenants.2.3x leverage ratio at results. Maximum is 3.5x before breach. Goes down to 3.25x early 2023.Now EBITDA down 10-15%. So ratio goes up 10-15%.Their debt is also in USD and EUR. So that's possibly another 5-10% increase in the ratio.After today's share price fall, debt will overshadow equity. Not a good place to be in. Classic further decline in share price as investors fret on possible outcomes. |
Posted at 16/9/2022 09:36 by brucie5 Edmundshaw, what you say is fairly indisputable - it could go either way! But this epitomises the dilemma that many value+income investors are facing currently, in holding/buying what they consider to be solid companies yielding great free cash flow, only to see the face value of the shares getting trashed.One way of looking at it might be to ask what you would do if SYNT was an IT - would you have the confidence to buy down the cycle into the abyss, knowing that the collective risk of the vehicle would prevent complete loss of capital? My answer? Probably - I would certainly feel much MORE confident in doing so, while seeking to hold some capital back for the absolute nadir - if that's possible to time. Added to which is the precondition of any share being held in such an IT: is it producing a sustainable market busting dividend, as far as one can tell? Added to which, are others, with similar investing priorities seeing value in these shares at these levels? Think directors, pension companies... Added to which: are you able to capitalise on the decline in the share price to buy down and increase your dividend average? And finally, step back a moment: this is not of course an IT, it is a single share. So, of course one needs to ask oneself, is this the only share in your folio, whose complete value destruction would mean capital wipeout? So I hold onto these. And unless the story changes, like GMPF, I will in due course be adding. |
Posted at 11/8/2022 14:42 by davebowler Investors Chronicle -FactSet consensus expects earnings to rise to 39p in 2023 which gives a very affordable 2023 PE ratio of five. Earnings aren’t going to race forward, but at these prices there looks to be value here. Buy. |
Posted at 17/5/2022 09:08 by montyhedge If price gets to a new trading range 345p - 355p before 1st June, then falls in line with ex dividend say 21p -22p.I think everyone happy, momentum traders, value investors, income investors, short term traders, the only ones not happy bears. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
